Kareem has more than ten years of experience building partnerships and executing a range of deals, including transformative collaborations and acquisitions, in the cell and gene therapy space. He is responsible for business and corporate development as ElevateBio creates and operates a portfolio of cell and gene therapy companies to develop life-transforming medicines for patients.
Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offering (IPO) and private Series B and C fundraising rounds, helping to raise over $200 million. While at Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). He also led the B-cell maturation antigen (BCMA) collaboration with bluebird bio and the $1 billion, 10-year collaboration with Juno Therapeutics, focused on Chimeric Antigen Receptor Technology (CAR-T) and T-cell Receptor (TCR) technologies. Kareem started his career at Vertex Pharmaceuticals in formulation development.
Education & Accomplishments
Kareem graduated magna cum laude with a degree in Chemical Engineering from Brown University and received his MBA from Harvard Business School.
Interested in working with people like Kareem? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.